The Medicines and Healthcare Products Regulatory Agency (MHRA) is expected to approve SpectraLIT, a COVID-19 diagnostic test that can return results within 20 seconds. The device is currently undergoing registration with the MHRA and, following approval, will be available in the UK.

Unlike many COVID-19 tests, SpectraLIT can detect the virus from non-invasive mouthwash samples, as well as more traditional nasal swabs. The device utilises AI and spectral analysis to assess the contents of a sample and make a diagnosis within 20 seconds.

The device’s speed of use, non-invasiveness compared to tests requiring nasopharyngeal swabs and low cost mean that it could prove valuable in enabling the UK to reopen from COVID-19 lockdown, with the final restrictions set to lift on July 19.

Inventive Health CEO Adrian Stevens said: “SpectraLIT moves the science of physics into medicine. By making point-of-care testing for COVID-19 simple and quick, SpectraLIT can help protect the community as we return to open-border travel, enable sports venues to operate at full capacity, ensure care homes can safely welcome visitors, permit the reopening of nightclubs and reopen schools and universities to face to face learning.”

“PCR testing undeniably remains the gold standard but scaling laboratory testing is also troublesome and costly. Likewise, the time needed to perform and receive a result from a lateral flow test renders them impractical for larger groups. Whatever the venue, the ability to receive a highly reliable result in near real-time means SpectraLIT helps open the door to safely resuming normal day-to-day activities.”

Contact us


Tel: +44 (0)1424 777745

Fax: +44 (0)1424 777746



Kirkham Young Ltd.
The Old Court House
North Trade Road
East Sussex
TN33 0EX